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I
n  today’s  open  Medicine,  steven  Lewis  brings 
forth provocative commentary on the appointment of 
Dr. Bernard Prigent, vice-president of medical affairs 
for Pfizer Canada, to the governing council of the Can-
adian Institutes of Health Research (CIHR). He outlines a 
number of arguments against the appointment that centre 
around conflict of interest, and places a spotlight on the 
diverging agendas of pharmaceutical companies (whose 
primary  obligation  is  to  serve  their  shareholders)  and 
CIHR (which must, as a publicly funded institution, serve 
the public interest). He recounts notable dark episodes 
when public safety was compromised by products that 
were highly profitable for pharmaceutical companies, and 
expresses the general concern that Dr. Prigent’s appoint-
ment heralds a new era of potentially troubling industry 
influence on Canada’s health research agenda.      
Lewis is not alone in his views: between November 25 
and December 25, 2009, over 4300 people signed an on-
line petition calling for the withdrawal of the appointment 
(http://gopetition.com/online/32371/signatures.html). 
Vocal concern led to a review of the appointment in two 
hearings by the House of Commons Standing Committee 
on Health; after spirited debate, a motion to recommend 
the withdrawal of the appointment was defeated. 
As the defeat shows, there are also defenders of the 
appointment,  and  they  range  beyond  the  members 
of  the  Standing  Committee.  To  broaden  our  readers’ 
understanding of the debate, Open Medicine invited the 
president of the CIHR, Dr. Alain Beaudet, who recom-
mended Dr. Prigent for the appointment, to provide a 
commentary to accompany Lewis’s article. Karen Spier-
kel, CIHR’s director of communications and public out-
reach, provided an official response for the agency that 
highlighted the following points (quoted directly):   
•  The CIHR Act specifies that Governing Council members 
are appointed by the Governor in Council. [Open Medicine 
note: The Governor in Council is the Governor General of 
Canada.] Section 7(4) of the CIHR Act outlines the appoint-
ment criteria as “the Governor in Council shall appoint as 
members of the Governing Council women and men who 
are able to contribute to the achievement of the objective of 
the CIHR in the overall interests of Canadians. The Gover-
nor in Council shall consider appointing women and men 
who reflect the highest standards of scientific excellence 
and women and men who reflect a range of relevant back-
grounds and disciplines.”
•  Dr. Prigent has been appointed for his skills, experience and 
personal competencies. He is an experienced strategic deci-
sion maker, with a keen understanding of research and devel-
opment partnerships between public and private institutions. 
CIHR has just renewed its Strategic Plan and a key action is 
to refine activities with respect to commercialization.
•  Dr. Prigent’s extensive experience in commercialization and 
pharmaceutical development will be critical to moving this 
forward and to achieve our mandate with respect to cures 
and treatments and facilitating commercialization.
•  Dr. Prigent will not be able to influence CIHR funding to 
specific research proposals. As a member of Governing 
Council, Dr. Prigent will make high level budget decisions; 
however, he will not make decisions with respect to which 
researchers/projects will be funded, as this is the respon-
sibility of the Scientific Council, based on the advice of 
individual peer review panels. 
•  All Governor in Council appointments must observe the 
Conflict of Interest Act, the Ethical Guidelines for Public Of-
fice Holders and the Guidelines for the Political Activities of 
Public Office Holders as a condition of appointment. These 
documents, along with general background on the Governor 
in Council appointment process, are available at the follow-
ing link:  www.appointments-nominations.gc.ca/prsnt.asp? 
page=Process&lang=eng  
These points were reinforced by Dr. Beaudet when he and 
Dr. Prigent spoke on the appointment to the members of the 
Standing Committee. Because the first of the two commit-
tee meetings is the only public forum in which Dr. Beaudet 
and Dr. Prigent have discussed the appointment and an-
swered questions about it, the Open Medicine editors here 
present extracts from that meeting for the reader’s bene-
fit. The extracts have been carefully selected to present in 
an unbiased way what Dr. Beaudet and Dr. Prigent had 
to say. The entire transcripts of both committee meetings 
are available from the House of Commons website in PDF 
form  at  http://www2.parl.gc.ca/content/hoc/Committee 
/ 4 0 2 / H E S A / E v i d e n c e / E V 4 2 7 5 1 6 5 /HESAEV47-E.PDF  and  http://www2.parl.gc.ca/con-
tent/hoc/Committee/402/HESA/Evidence/EV4302528/ 
HESAEV49-E.PDF.
CIHR’s stance is clearly that the strategic enhance-
ment of commercialization activities is the central ele-
ment supporting this appointment, and that in this realm 
Dr. Prigent is a highly competent individual. The CIHR 
statement also touches on the guidelines in place to at 
least partially manage conflict of interest when it arises.     
Open  Medicine’s  editorial  team  intentionally  stops 
here in presenting this controversy, respecting the con-
flicting  views  on  this  issue.  As  health  care  providers, 
teachers and researchers, we increasingly need to make 
informed decisions around transparency, accountability 
and conflict of interest. Through the commentary and 
Standing Committee extracts we seek simply to inform 
the  scientific  community  and  stimulate  reflection  and 
thoughtful  dialogue  among  stakeholders  on  the  chal-
lenges of reconciling potential conflict of interests with 
the  contributions  that  industry  partners  can  make  in 
moving scientific discoveries into the applied health care 
marketplace.  
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